Moderna/$MRNA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Ticker
$MRNA
Sector
Primary listing
Employees
5,800
Headquarters
Website
Moderna Metrics
BasicAdvanced
$9.3B
-
-$7.53
1.93
-
Price and volume
Market cap
$9.3B
Beta
1.93
52-week high
$52.08
52-week low
$23.15
Average daily volume
11M
Financial strength
Current ratio
3.926
Quick ratio
3.555
Long term debt to equity
7.426
Total debt to equity
7.884
Interest coverage (TTM)
-125.88%
Profitability
EBITDA (TTM)
-3,065
Gross margin (TTM)
-71.44%
Net profit margin (TTM)
-94.31%
Operating margin (TTM)
-106.34%
Effective tax rate (TTM)
1.43%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
-14.78%
Return on equity (TTM)
-27.50%
Valuation
Price to revenue (TTM)
2.978
Price to book
0.98
Price to tangible book (TTM)
0.99
Price to free cash flow (TTM)
-2.619
Free cash flow yield (TTM)
-38.18%
Free cash flow per share (TTM)
-9.067
Growth
Revenue change (TTM)
-39.05%
Earnings per share change (TTM)
-50.99%
3-year revenue growth (CAGR)
-48.85%
3-year earnings per share growth (CAGR)
-38.82%
What the Analysts think about Moderna
Analyst ratings (Buy, Hold, Sell) for Moderna stock.
Bulls say / Bears say
Moderna posted Q2 2025 revenue of $142 million, exceeding expectations by 26%, and an adjusted loss of $2.13 per share, helped by stronger spring COVID booster demand and $800 million in cost savings (Reuters).
The FDA approved Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE, for people 65 and older and those 12–64 at risk in May 2025, adding a compliant product to its lineup that meets tougher regulatory requirements (Reuters).
Moderna’s experimental flu vaccine, mRNA-1010, showed 26.6% higher efficacy than GSK’s approved flu shot in a late-stage trial, demonstrating its pipeline's potential to broaden revenue in the face of COVID weakness (Reuters).
The company's Q2 2025 revenue fell 41% from a year earlier and it cut its 2025 sales outlook to $1.5–$2.2 billion due to delayed UK deliveries, highlighting dwindling COVID demand (Reuters).
Moderna's RSV vaccine, mRESVIA, recorded minimal sales in Q2 2025 despite FDA approval, reflecting difficulties with commercial uptake and reliance on CDC recommendations (Reuters).
The company scrapped its cytomegalovirus (CMV) vaccine, mRNA-1647, after it failed to hit main targets in a late-stage trial, marking a major pipeline setback and triggering a drop of more than 5% in the stock (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
Moderna Financial Performance
Revenues and expenses
Moderna Earnings Performance
Company profitability
Moderna News
AllArticlesVideos
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
Accesswire3 days ago
S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges
Investopedia6 days ago
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
Accesswire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Moderna stock?
Moderna (MRNA) has a market cap of $9.3B as of November 06, 2025.
What is the P/E ratio for Moderna stock?
The price to earnings (P/E) ratio for Moderna (MRNA) stock is 0 as of November 06, 2025.
Does Moderna stock pay dividends?
No, Moderna (MRNA) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Moderna dividend payment date?
Moderna (MRNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Moderna?
Moderna (MRNA) has a beta rating of 1.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.